View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 9, 2021

Coronavirus company news summary – J&J vaccine US allocations down 85% amid uneven production – Lilly/Incyte’s baricitinib misses primary endpoint in Phase III trial in hospitalised Covid-19 patients

By Chris Lo

According to the Centers for Disease Control and Prevention (CDC), the US government will allocate approximately 85% fewer doses of Johnson & Johnson’s Covid-19 vaccine to states next week due to uneven production, partly a result of issues at a Baltimore manufacturing facility. The week’s allocation is expected to drop to 785,500 doses from 4.95 million doses, although this data does not include allocations to a federal retail pharmacy programme.

Eli Lilly and Incyte have announced results from the Phase III COV-BARRIER study of baricitinib 4mg for treating hospitalised Covid-19 patients. The study did not meet statistical significance in 1,525 patients, although data revealed a 38% fall in deaths by the 28th day among patients treated with baricitinib along with standard-of-care treatment, including corticosteroids and/or remdesivir. Patients receiving baricitinib were 2.7% less likely to progress to ventilation or death, a difference that was not statistically significant.

The Institute of Public Health of Chile has granted emergency use approval to CanSinoBIO’s single-dose Covid-19 recombinant vaccine, Convidecia. It is the first single-dose vaccine to be approved for emergency use in Chile, and the first approval of Convidecia in South America. Interim Phase III trial results suggest the vaccine is 65.28% effective at preventing symptomatic Covid-19 28 days after dosing, with an efficacy rate of 90.07% in preventing severe illness 28 days after the single-dose vaccination.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU